Session 99 - 12th CROI

Home

Session 99 Poster Abstracts
Therapeutic Intervention during Primary Infection
Wednesday, 1:30 - 3:30 pm
Hall A

567	Long-term Benefit of Cyclosporin A Coupled with Highly Active Antiretroviral Therapy in Primary HIV-1 Infection M Khonkarly¹, G Tambussi², D Ciuffreda¹, C Tassan-Din², P A Bart¹, A Lazzarin², G Pantaleo¹, and Gian-Paolo Rizzardi*² ¹Univ Hosp, Lausanne, Switzerland and ²San Raffaele Sci Inst, Milan, Italy
568	Outcomes of HAART for Acute/Early HIV-1 Infection after Treatment Discontinuation Frederick Hecht*¹, L Wang², A Collier², J Margolick³, S Little⁴, M Markowtiz⁵, J Kilby⁶, E Daar⁷, S Holte², and AIEDRP Network ¹Univ of California, San Francisco, USA; ²Univ of Washington, Seattle, USA; ³Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, USA; ⁴Univ of California, San Diego, USA; ⁵Aaron Diamond AIDS Res Ctr, Rockefeller Univ, New York, NY, USA; ⁶Univ of Alabama at Birmingham, USA; and ⁷Univ of California, Los Angeles, USA
569	The Role of Hydroxyurea in Enhancing the Virological Control Achieved through Structured Treatment Interruption in Primary HIV Infection: Final Results from a Randomized Clinical Trial Mark Bloch*¹, D Smith², P Grey², D Quan¹, R McFarlane³, R Finlayson⁴, T Kelleher², J Zaunders², K Petoumenos², K Irvine², M Law², A Carr⁵, J Kaldor², and D Cooper² ¹Holdsworth House Gen Practice, Sydney, Australia; ²Natl Ctr in HIV Epidemiology and Clin Res, Univ of New South Wales, Sydney, Australia; ³407 Doctors, Darlinghurst, Australia; ⁴Taylor Square Private Clin, Darlinghurst, Australia; and ⁵St Vincent's Hosp, Darlinghurst, Australia
570	A Pilot Open-label Phase II Trial of the Safety and Efficacy of a Compact 3-Drug Antiretroviral Treatment Regimen for Subjects with Acute or Recent Primary HIV-1 Infection Constance A Benson*¹, T Campbell¹, S MaWhinney¹, E Connick¹, J Forster¹, G Ray¹, M Thompson², A Landay³, R Badaro⁴, E Netto⁴, F Judson⁵, F Pallela⁶, and R Schooley¹ ¹Univ of Colorado Hlth Sci Ctr, Denver, USA; ²AIDS Res Consortium of Atlanta, GA, USA; ³Rush Univ, Chicago, IL, USA; ⁴Federal Univ of Bahia, Salvador, Brazil; ⁵Denver Hlth Med Ctr, CO, USA; and ⁶Northwestern Univ, Feinberg Sch of Med, Chicago, IL, USA
571	Prognostic Factors of Clinical or Immunological Progression in Untreated Patients Diagnosed at the Time of Primary HIV-1 Infection: Results from the French PRIMO Cohort C Goujard¹, M Bonarek², Laurence Meyer*¹, F Bonnet², C Rouzioux³, C Deveau¹, M L Chaix³, J F Delfraissy¹, P Morlat², and PRIMO ANRS EP8 Study Group ¹Hosp Bicêtre, Paris, France; ²Hosp St André, Bordeaux, France; and ³Necker hosp, Paris, France